Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMVT-1402 phase 2b trial in Graves' disease
NL-OMON59690Phase 2Recruiting
- Sponsor
- Immunovant, Inc.
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Graves' disease comparing IMVT-1402 dose 1 with Placebo (2 arms). Primary endpoint: Proportion of participants who are euthyroid and off antithyroid drugs at Week 26. Started Jan 2026; status: recruiting.
02
Drugs
IMVT-1402
03
Conditions
Graves' disease
Beyond the preview
Go deeper on NL-OMON59690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59690.